Clinical Trial Search

Primary: Percentage of Participants Who Experienced In-lesion Restenosis as Measured by Quantitative Coronary Angiography (QCA) at 6 Months Post-procedure — 16.9 Percentage of…

Primary: Change in Hb Concentration (g/dL) From Baseline to the Average of the Last 8 Weeks of Treatment Through Week 22 — 1.81; 1.59; 1.27 g/dL

Primary: Change From Baseline in Unified Parkinson's Disease Rating Scale (UPDRS) Parts II+III Score at Week 18 — -11.0; -12.8; -6.1 Percentage of change from baseline — p=0.0001

Primary: Mean Percentage of Days With Worsening Asthma (as Measured on Daily Diaries) in Pediatric Asthmatic Participants — 27.23; 24.26 Percentage of Days

Primary: Number of Subjects With American College of Rheumatology (ACR) Criteria Improvement of at Least 20%, 50%, and 70% (ACR20/50/70 Responders, Respectively) — 66; 48; 28; 64…

Primary: Maintenance of Wakefulness Test (MWT) — 2.3; -1.3 Minutes — p=0.0003

Primary: Multiple Sleep Latency Test (MSLT) — 2.0; 3.7; 3.7; 2.7 Minutes — p=0.1236

Primary: Mean Response at Day 30 to the Patient-rated Relief Assessment Questionnaire — 2.7; 2.5 Unit on PRRA scale

Primary: Decrease in Seated Diastolic Blood Pressure From Baseline to 8 Weeks — 13.49; 5.47 mmHg — p=<0.0001

Primary: Permanent Product Measure of Performance (PERMP) Total Score Over the Treatment Day in the Crossover Phase — 312.9; 289.5 Units on a scale — p=<0.0001

Primary: Change From Baseline in Triglycerides Levels by Treatment Group at Maintenance Month 6 — 2.65; 10.39 mg/dL — p=0.0141

Primary: Clinical Response — 227; 228; 53; 52 participants

Primary: Percentage of Participants Responding at Week 48 Based on the Food and Drug Administration (FDA) Time to Loss of Virologic Response (TLOVR) Algorithm — 55.3; 51.8…

Primary: Clinical Response — 358; 364; 59; 57 patients

Primary: Incidence Rate of HPV 6/11/16/18 Related Persistent Infection, Genital Warts, VIN, VaIN, Vulvar Cancer, Vaginal Cancer, Cervical Dysplasia, Cervical AIS, and Cervical…